Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway

The Pathobiology of Diabetic Complications

Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · see citing works

Diabetic Kidney Disease: Challenges, Progress, and Possibilities

Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · see citing works

Chronic kidney disease

Kalantar‐Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,572 · see citing works

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · see citing works

Update on Diabetic Nephropathy: Core Curriculum 2018

Umanath, K., & Lewis, J. B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.10.026 · Cited by 1,009 · see citing works

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1× · see citing works

An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines

Selby, N. M., & Taal, M. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14007 · Cited by 810 · see citing works

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684 · see citing works

Diabetes and Kidney Disease: Role of Oxidative Stress

Jha, J. C., Banal, C., Chow, B. S. M., Cooper, M. E., & Jandeleit-Dahm, K. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6664 · Cited by 660 · see citing works

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · see citing works

Innate immunity in diabetes and diabetic nephropathy

Wada, J., & Makino, H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.175 · Cited by 432 · see citing works

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · see citing works

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407 · see citing works

IL-17 in Chronic Inflammation: From Discovery to Targeting

Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 400 · see citing works

The role of the complement system in diabetic nephropathy

Flyvbjerg, A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.31 · Cited by 397 · see citing works

The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update

Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works

Streptozotocin‐Induced Diabetic Models in Mice and Rats

Wu, K. K., & Huan, Y. (2008) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0547s40 · Cited by 376 · see citing works

AGE, RAGE, and ROS in Diabetic Nephropathy

Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 369 · see citing works

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345 · see citing works

Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms

Gnudi, L., Coward, R. J., & Long, D. A. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.07.002 · Cited by 331 · see citing works

Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy

Sifuentes-Franco, S., Padilla-Tejeda, D. E., Carrillo-Ibarra, S., & Miranda‐Díaz, A. G. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1875870 · Cited by 304 · see citing works

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.

Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299 · see citing works

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272 · see citing works

Experimental diabetes induced by alloxan and streptozotocin: The current state of the art

Radenković, M., Stojanović, M., & Prostran, M. S. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.11.004 · Cited by 271 · see citing works

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256 · see citing works

Diabetic nephropathy: Is there a role for oxidative stress?

Sagoo, M. K., & Gnudi, L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.040 · Cited by 233 · see citing works

Signaling of interleukin-17 family cytokines in immunity and inflammation

Chang, S. H., & Dong, C. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.11.022 · Cited by 231 · see citing works

Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives

Tănase, D. M., Gosav, E. M., Anton, M. I., Floria, M., Isac, P. N. S., Hurjui, L. L., Tărniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezuș, C. (2022) · Biomolecules · doi:10.3390/biom12091227 · Cited by 203 · see citing works

Signalling from the periphery to the brain that regulates energy homeostasis

Kim, K., Seeley, R. J., & Sandoval, D. A. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.8 · Cited by 181 · see citing works

Reactive Oxygen Species Modulate the Barrier Function of the Human Glomerular Endothelial Glycocalyx

Singh, A. K., Ramnath, R. D., Foster, R. R., Wylie, E. C., Fridén, V., Dasgupta, I., Haraldsson, B. S., Welsh, G. I., Mathieson, P. W., & Satchell, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055852 · Cited by 163 · see citing works

IL-17 in the immunopathogenesis of spondyloarthritis

Taams, L. S., Steel, K. J. A., Srenathan, U., Burns, L. A., & Kirkham, B. W. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0044-2 · Cited by 159 · see citing works

Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention

Ma, X., Ma, J., Leng, T., Yuan, Z., Hu, T., Liu, Q., & Shen, T. (2023) · Renal Failure · doi:10.1080/0886022x.2022.2146512 · Cited by 151 · see citing works

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy

Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 149 · see citing works

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 147 · see citing works

Mouse Models of Diabetes, Obesity and Related Kidney Disease

Glastras, S. J., Chen, H., Teh, R., McGrath, R. T., Chen, J., Pollock, C. A., Wong, M. G., & Saad, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162131 · Cited by 145 · see citing works

Tirzepatide: First approval

Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144 · see citing works

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity &amp; Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138 · see citing works

Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy

Lavoz, C., Matus, Y. S., Orejudo, M., Carpio, J. D., Droguett, A., Egido, J., Mezzano, S. A., & Ruiz‐Ortega, M. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.031 · Cited by 114 · see citing works

Mechanical Forces in Diabetic Kidney Disease

Gnudi, L., Thomas, S. M., & Viberti, G. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121362 · Cited by 113 · see citing works

The Origin and Understanding of the Incretin Concept

Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102 · see citing works

Comparative Trial of N-Acetyl-Cysteine, Taurine, and Oxerutin on Skin and Kidney Damage in Long-Term Experimental Diabetes

Odetti, P. R., Pesce, C. M., Traverso, N., Menini, S., Maineri, E. P., Cosso, L., Valentini, S., Patriarca, S., Cottalasso, D., Marinari, U. M., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.2.499 · Cited by 97 · see citing works

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Novikoff, A., O’Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R. D., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95 · see citing works

Interleukin 17A promotes diabetic kidney injury

Ma, J., Li, Y. J., Chen, X., Kwan, T., Chadban, S. J., & Wu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-38811-4 · Cited by 87 · see citing works

Molecular Mechanisms of Diabetic Kidney Disease

Rico-Fontalvo, J. E., Aroca, G., Cabrales, J., Daza-Arnedo, R., Yánez, T. R., Martínez‐Ávila, M. C., Uparella-Gulfo, I., & Raad-Sarabia, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158668 · Cited by 84 · see citing works

Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review

Jana, S., Mitra, P., & Roy, S. (2022) · Diseases · doi:10.3390/diseases11010008 · Cited by 67 · see citing works

Correction: Proteomic Identification of Mitochondrial Targets of Arginase in Human Breast Cancer

Singh, R., Avliyakulov, N. K., Braga, M., Haykinson, M. J., Martinez, L., Singh, V., Parveen, M., Chaudhuri, G., & Pervin, S. (2013) · PLoS ONE · doi:10.1371/annotation/7e9bf57e-a45f-4a22-95ee-eece21d282c8 · Cited by 46 · see citing works

Ginsenoside Rb1 exerts antiarrhythmic effects by inhibiting INa and ICaL in rabbit ventricular myocytes

Liu, Z., Song, L., Zhang, P., Cao, Z., Hao, J., Tian, Y., Luo, A., Zhang, P., & Ma, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-57010-9 · Cited by 42 · see citing works

Diabetic complications and prospective immunotherapy

Reynolds, L., Luo, Z., & Singh, K. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1219598 · Cited by 41 · see citing works

Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response

Cao, Z., Zhao, H., Fan, J., Shen, Y., Han, L., Jing, G., Zeng, X. L., Jin, X., Zhu, Z., Bian, Q., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01304-5 · Cited by 26 · see citing works

Pathophysiology, Etiology, Epidemiology of Type 1 Diabetes and Computational Approaches for Immune Targets and Therapy

Dariya, B., Chalikonda, G., Srivani, G., Alam, A., & Nagaraju, G. P. (2019) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2019033126 · Cited by 25 · see citing works

IL‐17A‐mediated ERK1/2/p65 signaling pathway is associated with cell apoptosis after non‐alcoholic steatohepatitis

Pan, Y., Ren, X., Zhang, Y., Lv, J., Zeng, Q., Zhang, H., & Yu, Z. (2018) · IUBMB Life · doi:10.1002/iub.1960 · Cited by 14 · see citing works

A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease

Alshehri, G. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Fawzy, M. N., Waheed, H. J., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177979 · Cited by 18 · see citing works

Multifaceted roles of IL-17 in bone and tendon health

Shen, J., Chen, Y., Zhang, Y. H., Zhang, C., & Liu, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139498 · Cited by 16 · see citing works

The effect and potential mechanisms of per- and polyfluoroalkyl substances (PFAS) exposure on kidney stone risk

Cui, Y., Wu, A., Liu, H., Zhong, Y., & Yi, K. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118087 · Cited by 13 · see citing works

Advances in Understanding Diabetic Kidney Disease Progression and the Mechanisms of Acupuncture Intervention

Shan, J., Cao, Z., & Yu, S. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s490049 · Cited by 13 · see citing works

Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway

Hegab, I. I., El‐Horany, H. E., Abd‐Ellatif, R. N., Nasef, N. A., okasha, A. H., Emam, M. N., Hassan, S., Elseady, W. S., Radwan, D. A., El‐Esawy, R. O., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010001 · Cited by 9 · see citing works

Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease

Ma, J., Tao, M., Zhang, W., Zhou, L., Zhang, H., Li, F., Zhang, H., Yao, D., Lu, W., & Wang, M. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1715024 · Cited by 8 · see citing works

Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide

Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 6 · see citing works

Immune and Vascular Function in Cardiometabolic Disorders: Interplay With Sex Differences and Impact on Incretin Therapy

Muralikrishnan, A. S., Biasin, V., Zabini, D., & Osto, E. (2025) · Acta Physiologica · doi:10.1111/apha.70091 · Cited by 5 · see citing works

Association between systemic inflammatory indicators on admission and mortality in critically ill patients with diabetic kidney disease based on the MIMIC-IV database: a cohort study

Shen, G.-Y., Wang, Q., Lv, S., Huang, Z.-D., Zhang, R.-L., & Wu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503667 · Cited by 5 · see citing works

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide

Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.04.044 · Cited by 5 · see citing works

Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models

Tartau, C. G., Boboc, I. K. Ş., Mititelu-Tarțău, L., Bogdán, M., Bucă, B. R., Pavel, L. L., & Amălinei, C. (2025) · Pharmaceuticals · doi:10.3390/ph18050670 · Cited by 4 · see citing works

The role of the incretin GIP in inflammation

Rossi, G., Bucciarelli, L. G., Cimino, V., & Fiorina, P. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02719-w · Cited by 4 · see citing works

Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis

Alawaji, R., Abdel‐Bakky, M. S., Ali, H. M., Aljuhani, M. A., Alshammari, A. A. A., Kamal, H. K., Khoja, M. T., Alsehemi, K., Korani, M. A., & Said, E. S. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70083 · Cited by 4 · see citing works

Astragalus polysaccharide alleviates diabetic nephropathy via SIRT1-dependent activation of FOXO3a/BNIP3 pathway to enhance podocyte autophagy

Guo, M., Dai, Y., & Zhuang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-33000-y · Cited by 4 · see citing works

The mechanistic role of tirzepatide in atherosclerosis: A review

Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Saad, ‏. M., Waheed, H. J., Jabir, M. S., Al-Gareeb, A. I., & Albuhadily, A. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147734 · Cited by 4 · see citing works

Curcumin ameliorates benzalkonium chloride-induced dry eye disease in mice

Liu, Z., Li, Y., Wen, Y., Bao, J., Tian, L., & Jie, Y. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110509 · Cited by 4 · see citing works

Metabolic-associated enthesitis: a review on pathophysiology, clinical relevance, diagnostic challenges, and perspective on target treatments

Lisco, G., Tullio, A. D., Zupo, R., Prete, M., Piazzolla, G., Racanelli, V., & Triggiani, V. (2025) · Immunologic Research · doi:10.1007/s12026-025-09655-0 · Cited by 3 · see citing works

Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice

Bittencourt, J. D. O. A., Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124155 · Cited by 3 · see citing works

Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide

Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4 · see citing works

Therapeutic role of Crateva religiosa in diabetic nephropathy: Insights into key signaling pathways

Ali, M., Irfan, H. M., Alamgeer, Ullah, A., Abdellattif, M. H., Elodemi, M., Zubair, M., Khan, A., & Al‐Harrasi, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324028 · Cited by 2 · see citing works

Dual GLP-1/GIP agonist tirzepatide modulates hepatic mitochondrial fusion–fission gene expression and oxidative stress in diabetic rats

Fakhir, S. D., Arif, I. S., & Waheed, H. J. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e175259 · Cited by 2 · see citing works

Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation

Tan, L., Liu, J., Shi, R., & Liu, Y. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107581 · Cited by 2 · see citing works

Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements

Taha, M. M. E., Abdelwahab, S. İ., Oraibi, O., Madkhali, M. A., Alhazmi, A., Jeraiby, M., Abdullah, S. M., Farasani, A. M., Moshi, J. M., Khamjan, N. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04574-1 · Cited by 2 · see citing works

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation

Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 1 · see citing works

Investigation of the Potential Pharmacological Substance Basis and Mechanism of Action of Xuantu Granules in Treating Diabetic Kidney Disease Based on UHPLC-Q-Exactive-HRMS and Bioinformatics

Fan, J., Kong, C., Yu, B., Wang, R., & Qi, Z. (2025) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073364424241202111833 · Cited by 1 · see citing works

Anti-obesity Treatments with Anti-inflammatory and Antioxidant Potential and their Effects on Obesity-related Metabolic and Cardiovascular Disorders: A Narrative Review

Varra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328392698250818071803

Evaluation of The Antioxidant, Hypolipidemic, and Pancreatic Histological Alterations Effects of Tirzepatide in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats

Fakhir, S. D., Arif, I. S., Alqallaf, S. M., & Waheed, H. J. (2026) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v26i1.1347

Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study

Wu, J., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1769425

Xanthotoxol alleviates tubulointerstitial inflammation in diabetic kidney disease by targeting the HSP90αβ1/NLRP3 signaling pathway

Jiang, W., Yang, H., Ren, J., Tang, L., Gong, J., Fang, H., Xu, S., Pang, J., & Su, D. (2026) · Applied Biological Chemistry · doi:10.1186/s13765-026-01108-y

Diabetic Nephropathy and Oxidative Stress

Al-Sabti, A. S. S., Al-Musawi, N. J. T., & Al-Kufaishi, A. M. A. (2026) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_37_26

Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study

Wu, J., Lee, K.-W., Huang, S. H. M., Chang, H.-Y., & Lin, Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06269-8

Peimisine ameliorates diabetic nephropathy by attenuating inflammation and ferroptosis through inhibition of the JAK/STAT pathway

Qu, J., Wang, S., Wang, J., Fan, D., Liu, X. Q., Zhang, X., & Huang, N. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115125

Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults

Su, Y., Gau, S., & Shiue, Y.-L. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70440

Exploring the anti-inflammatory targets of Gui-qi-yi-shen granules in diabetic nephropathy: insights from network pharmacology, transcriptomics, and experimental verification

Cao, J., Lu, M.-D., Bi, P., 唐玥雯, & Wan, F. (2026) · RSC Advances · doi:10.1039/d6ra03780a

Glucagon-like peptide-1 as a recovery biomarker after traumatic brain injury in patients with obesity: Preliminary results

Eagle, S. R., Basantani, M. K., Puccio, A., Okonkwo, D. O., & Kershaw, E. E. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126232

GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress

Tian, Y., Tian, R., He, J., Guo, Y., Yan, P., Cheng, Y., Li, R., & Wang, B. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113877 · Cited by 19 · see citing works

Interleukin 17A promotes diabetic kidney injury

Ma, J., Li, Y. J., Chen, X., Kwan, T., Chadban, S. J., & Wu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-38811-4 · Cited by 87 · see citing works

Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis

Mohamed, R., Jayakumar, C., Chen, F., Fulton, D. J., Stepp, D. W., Gansevoort, R. T., & Ramesh, G. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111136 · Cited by 126 · see citing works

Diphenyl diselenide ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats via suppressing oxidative stress and inflammation

Wang, X., Li, C., Huan, Y., Cao, H., Sun, S., Lei, L., Liu, Q., Liu, S., Ji, W., Huang, K., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109427 · Cited by 29 · see citing works

Telmisartan attenuates diabetic nephropathy by mitigating oxidative stress and inflammation, and upregulating Nrf2/HO-1 signaling in diabetic rats

Antar, S. A., Abdo, W. S., Taha, R. S., Farage, A. E., EI-Moselhy, L. E., Amer, M. E., Monsef, A. S. A., Hamid, A. M. A., Kamel, E. M., Ahmeda, A. F., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120260 · Cited by 72 · see citing works